CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    Employees

    29,000

CSL Ltd News & Analysis

etfs

Future Focus: 3 ETFs for Australian equity exposure

Weighting matters more than you think when it comes to diversification, performance and risk.
personal-finance

Investor Playbook: What these ASX heavyweights reveal about your portfolio

What really drives your returns?
personal-finance

The State of the Australian Investor 2026

Data on how Australian retail investors think and act.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,711.10125.50-1.42%
CAC 408,080.7466.09-0.81%
DAX 4025,463.81272.43-1.06%
Dow JONES (US)49,097.061,101.11-2.19%
FTSE 10010,452.6898.49-0.93%
HKSE22,841.62453.13-1.95%
NASDAQ23,879.20550.69-2.25%
Nikkei 22557,097.592,346.62-3.95%
NZX 50 Index14,164.7682.49-0.58%
S&P 5007,175.83147.80-2.02%
S&P/ASX 2008,609.90120.50-1.38%
SSE Composite Index3,577.080.54-0.02%

Market Movers